List of Excipients in Branded Drug CHILDRENS LORATADINE

« Back to Dashboard

Generic Drugs Containing CHILDRENS LORATADINE

Company	Ingredient	NDC	Excipient
Pharmaceutical Associates Inc	loratadine	0121-0849	ANHYDROUS CITRIC ACID
Pharmaceutical Associates Inc	loratadine	0121-0849	BUTYLATED HYDROXYANISOLE
Pharmaceutical Associates Inc	loratadine	0121-0849	GLYCERIN
Pharmaceutical Associates Inc	loratadine	0121-0849	POLYSORBATE 80
Pharmaceutical Associates Inc	loratadine	0121-0849	PROPYLENE GLYCOL
Pharmaceutical Associates Inc	loratadine	0121-0849	SODIUM BENZOATE

What are the Most Frequently-Used Excipients in CHILDRENS LORATADINE?

# Of NDCs	Excipient
9	ANHYDROUS CITRIC ACID
8	ASPARTAME
21	BUTYLATED HYDROXYANISOLE
8	CELLULOSE, MICROCRYSTALLINE
9	CITRIC ACID MONOHYDRATE
3	COCHINEAL

Children's Loratadine Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 28, 2026

Children's loratadine is an established OTC antihistamine with limited core patent protection and substantial formulation differentiation potential. The strongest opportunities are sugar-free oral liquids, dye-free products, improved taste masking, dose-accurate delivery systems, unit-dose packaging, and private-label or regional licensing. Commercial value depends less on active-ingredient exclusivity than on palatability, stability, pediatric usability, manufacturing efficiency, and brand trust.

What is Children's Loratadine and How Is It Regulated?

Children's loratadine is an oral formulation of loratadine, a second-generation H1 antihistamine used for temporary relief of allergy symptoms and hives. In the United States, common pediatric strengths are:

Age group	Typical dose	Common presentation
Children 2 to under 6 years	5 mg once daily	5 mg/5 mL oral solution or syrup
Children 6 years and older	10 mg once daily	10 mg tablet, chewable, orally disintegrating tablet, or 10 mg/10 mL liquid
Children under 2 years	Medical advice required	Product labeling varies

FDA OTC labeling generally limits self-treatment in children under 2 years and requires age-specific directions. Loratadine is recognized as an OTC antihistamine active ingredient under FDA’s antihistamine monograph framework and is marketed through branded, generic, store-brand, and international products.[1]

The principal commercial forms are:

• 5 mg/5 mL oral solution or syrup
• 10 mg/10 mL oral solution
• 5 mg chewable tablets
• 10 mg chewable tablets
• 10 mg orally disintegrating tablets
• Standard 10 mg tablets for older children and adolescents

The active ingredient is inexpensive and widely available. The commercial product is therefore defined by formulation performance, manufacturing cost, packaging, regulatory execution, and consumer acceptance.

What Excipients Are Used in Children's Loratadine Products?

The excipient profile varies by manufacturer, dosage form, country, and flavor system. Common excipient classes include:

Excipient class	Typical function	Commercial and technical considerations
Purified water	Liquid vehicle	Requires microbial control and validated packaging
Sucrose	Sweetener and viscosity contributor	Improves taste but creates sugar, dental, and diabetic-use concerns
Sorbitol	Sugar alcohol sweetener and bulking agent	Supports sugar-free positioning; excessive exposure may cause gastrointestinal effects
Glycerin	Co-solvent, humectant, mouthfeel modifier	Can improve texture and reduce crystallization
Propylene glycol	Co-solvent	Useful for flavor and preservative systems; pediatric exposure must be controlled
Citric acid and citrate salts	pH adjustment and buffering	Influences taste, preservative efficacy, and stability
Sodium benzoate or benzoic acid	Preservative	Effective in acidic systems; requires controlled pH
Flavor systems	Taste masking	One of the main sources of differentiation
Colorants	Product identification and appearance	Dye-free versions address parent and retailer preferences
Cellulose derivatives	Suspending or thickening agent	Can improve dose uniformity and mouthfeel
Magnesium stearate and colloidal silicon dioxide	Tablet processing	Affect flow, compression, disintegration, and powder handling
Crospovidone or croscarmellose sodium	Tablet disintegration	Important for chewable and orally disintegrating formats

DailyMed product labels provide the legally relevant inactive-ingredient composition for individual products. The composition of one Children's Claritin, generic loratadine solution, or store-brand product cannot be assumed to apply to another.[2]

Which Excipients Matter Most in Pediatric Loratadine?

Taste, dose accuracy, preservative selection, and sugar content have the greatest commercial impact.

Loratadine has a bitter taste that can become more noticeable in aqueous formulations. Sweeteners alone may not adequately mask the bitterness. A successful formulation generally combines sweetness, flavor, pH control, viscosity, and mouth-coating properties. Excessive viscosity can interfere with dose withdrawal and create residue around the dosing syringe.

The formulation must also maintain chemical and microbiological stability during the labeled in-use period. A low-pH system can improve preservative performance but may create sourness or irritate the mouth. The optimal formulation therefore balances pH, buffer capacity, flavor, preservative concentration, and patient acceptability.

What Excipient Strategies Create Commercial Differentiation?

How Can Sugar-Free Children's Loratadine Be Positioned?

Sugar-free oral liquid is the clearest product extension. Sorbitol, glycerin, sucralose, acesulfame potassium, or combinations of these ingredients can replace sucrose.

A sugar-free strategy can target:

• Children with diabetes or reduced sugar intake
• Parents seeking lower dental-caries exposure
• Pharmacies and retailers expanding pediatric wellness products
• Institutional buyers requiring sugar-free alternatives
• Consumers comparing private-label products with branded products

Sorbitol can improve viscosity and mouthfeel, but the label should account for gastrointestinal tolerance. A high-sorbitol system may be poorly accepted by some children. Glycerin can moderate mouthfeel but may produce a heavy or warming sensation at higher concentrations.

How Can Taste Masking Improve Pediatric Adherence?

Taste masking is the highest-value technical opportunity in liquid loratadine. Potential approaches include:

1. Optimized flavor combinations, such as fruit profiles designed to suppress bitterness rather than merely increase sweetness.
2. Polymer-based taste-masking systems for tablets or orally disintegrating tablets.
3. Ion-exchange resin complexes for immediate-release solid dosage forms.
4. Lipid or particulate barriers that reduce contact between loratadine and taste receptors.
5. Controlled pH and buffer adjustment to reduce perceived bitterness.
6. Viscosity modification that increases residence-time control without impairing swallowability.

The most practical commercial approach is usually an improved flavor and sweetener system because it has a lower development burden than a novel delivery technology. A genuinely superior taste profile can support brand switching and retailer differentiation, but it must be demonstrated through pediatric or adult sensory testing, stability work, and regulatory documentation.

What Are the Benefits of Dye-Free and Allergen-Aware Formulations?

Dye-free formulations address parental concerns about synthetic colorants and simplify retailer positioning. The commercial benefit is strongest when the product is combined with:

• Sugar-free labeling
• Gluten-free labeling where substantiated
• No artificial flavors
• Alcohol-free formulation
• Clear allergen-control statements
• A child-resistant but caregiver-friendly package

These claims must be supported by ingredient qualification, supplier controls, and applicable labeling requirements. “Clean label” positioning has greater value in consumer marketing than in patent strategy, but it can increase shelf differentiation in crowded OTC categories.

Can Preservative-Free Liquid Loratadine Be Commercialized?

Preservative-free multidose oral liquid is technically difficult because the product is repeatedly exposed to the environment. Viable commercial approaches include:

• Unit-dose cups or sachets
• Metered-dose pump bottles
• One-way valve dispensing systems
• Blow-fill-seal unit-dose packaging
• Small-volume packaging with short in-use periods
• Aseptic manufacturing, where economically justified

A preservative-free product may command a premium, but the packaging cost and supply-chain complexity can eliminate the margin advantage. Unit-dose packaging is more attractive for hospitals, travel, school health programs, and specialty retail than for mass-market family use.

What Formulations Are Protected by Loratadine Patents?

The original loratadine compound and early pharmaceutical patents are expired in the United States. Loratadine has been marketed for decades, and the active ingredient is available from multiple generic manufacturers.

IP category	Current commercial relevance
Original loratadine compound patents	Expired
Basic oral tablet patents	Expired or commercially non-blocking
Standard oral solution technology	Generally available; differentiation depends on formulation execution
Taste-masked tablets or ODTs	Potentially protectable if technically novel and non-obvious
Novel preservative-free packaging	Potentially protectable through formulation, container, or combination claims
New dosing devices	Potentially protectable through device and use claims
New pediatric combinations	Potentially subject to method-of-use and formulation claims
Manufacturing process improvements	Potentially protectable if they produce measurable advantages

The main opportunity is not a new loratadine molecule. It is a formulation or delivery patent covering a defined excipient combination, taste-masking system, dosage form, device, or stability advantage.

A formulation patent should claim more than routine substitution of sucrose with sorbitol. Stronger claims would require a demonstrated technical result, such as:

• Improved loratadine stability under accelerated conditions
• Reduced bitterness measured through validated sensory methodology
• Lower preservative concentration with equivalent antimicrobial performance
• Improved dose uniformity after repeated bottle use
• Faster disintegration without increased bitterness
• Reduced sedimentation or superior redispersibility
• Improved stability in a preservative-free multidose package

When Does Children's Loratadine Lose Exclusivity?

Loratadine has already lost practical market exclusivity. The product is an established OTC active ingredient, and generic and store-brand competition is extensive.

What Is the Orange Book Status of Children's Loratadine?

The Orange Book is primarily used for approved prescription and certain NDA-listed products. OTC loratadine products marketed under the OTC monograph system do not receive the same patent-centered commercial protection as a newly approved prescription drug.

For a specific branded NDA product, FDA’s Orange Book and associated FDA records must be reviewed for any listed patents or exclusivity. Standard pediatric loratadine liquids, chewables, and tablets generally do not have a meaningful remaining core patent barrier. A company developing a new product should therefore focus on its own formulation and device patents rather than relying on active-ingredient exclusivity.[3]

Are Paragraph IV Challenges Relevant to Loratadine?

Paragraph IV litigation is unlikely to be a central risk for ordinary OTC loratadine because the principal product category is governed by OTC regulation rather than a current prescription NDA patent estate. A Paragraph IV certification may matter only where a product is tied to a listed patent under an applicable NDA or abbreviated approval pathway.

The commercially relevant risks are instead:

• FDA monograph compliance
• Misbranding or unsupported labeling claims
• Inactive-ingredient qualification
• Manufacturing and stability failure
• Product-quality recalls
• Trademark and trade-dress disputes
• Device and packaging patent claims

What Is the FDA Regulatory Pathway for Pediatric Loratadine?

A standard Children's loratadine product can generally be developed under the applicable FDA OTC monograph if it meets the permitted active ingredient, dosage, route, labeling, and manufacturing requirements. A product outside the monograph may require an approved NDA or an appropriate FDA review pathway.

Key regulatory controls include:

• Use of loratadine at permitted OTC strengths
• Age-appropriate dosing directions
• Required warnings and labeling
• Drug Facts format
• Stability through expiration
• Microbial limits for oral liquids
• Container-closure compatibility
• Dose-delivery accuracy
• Inactive-ingredient safety
• Child-resistant packaging requirements where applicable

The FDA Inactive Ingredient Database can support excipient selection, but prior use at a given route and dosage does not automatically establish suitability for every pediatric formulation. The proposed concentration, maximum daily exposure, age group, and route must be evaluated as a complete product design.[4]

How Strong Is the Patent Estate for Children's Loratadine?

The patent estate is weak for conventional products and potentially moderate for differentiated delivery systems.

Product concept	Patent strength	Commercial defensibility
Standard 5 mg/5 mL syrup	Low	Brand, price, distribution, and flavor
Sugar-free liquid	Low to moderate	Formulation details may support narrow claims
Dye-free liquid	Low	Marketing and retailer access
Premium taste-masked liquid	Moderate	Stronger if supported by comparative data
Orally disintegrating tablet	Moderate	Formulation and process claims possible
Fast-dissolving chewable	Moderate	Possible claims around disintegration and taste
Preservative-free unit dose	Moderate	Packaging and formulation combination
Novel dosing syringe or pump	Moderate	Device claims and trade dress
New loratadine combination product	Variable	Regulatory and safety restrictions apply

The strongest protection would combine several layers:

1. Formulation claims.
2. Manufacturing-process claims.
3. Container-closure claims.
4. Dosing-device claims.
5. Trademark and trade dress.
6. Retailer or licensing agreements.

A single narrow excipient claim is vulnerable to design-around. A coordinated product platform is more durable.

What Generic Entry Risks Exist for Children's Loratadine?

Generic entry risk is high because:

• Loratadine is off-patent.
• Multiple suppliers can manufacture the active ingredient.
• Standard oral liquids use conventional excipients.
• Consumer switching costs are low.
• Retailers can launch private-label alternatives quickly.
• The product is generally not dependent on a complex device or biologic manufacturing process.

Generic competition is less damaging when the product has a clear point of difference, such as superior taste, a trusted pediatric dosing system, preservative-free unit-dose packaging, or strong retailer exclusivity.

A successful launch should avoid competing solely on active-ingredient price. A low-cost conventional liquid can achieve volume but is exposed to retailer margin pressure and rapid substitution.

Which Companies Are Competing in Children's Loratadine?

The competitive field includes:

• Bayer, through the Claritin brand in relevant markets
• Perrigo and other OTC private-label manufacturers
• Large generic drug manufacturers
• Regional consumer-health companies
• Contract development and manufacturing organizations
• Pharmacy and mass-retail private-label businesses

The competitive structure is fragmented. Brand recognition remains important, but pharmacies and mass retailers can substitute private-label loratadine where the formulation meets labeling, quality, and consumer expectations.

How Does Children's Loratadine Compare With Other Pediatric Antihistamines?

Product	Active ingredient	Key advantage	Main commercial constraint
Children's loratadine	Loratadine	Once-daily dosing and established safety profile	Heavy generic competition
Cetirizine products	Cetirizine	Strong allergy-category recognition	Some users report drowsiness
Fexofenadine products	Fexofenadine	Low-sedation positioning	Higher cost and formulation complexity in some markets
Diphenhydramine products	Diphenhydramine	Low cost and broad availability	Sedation and shorter dosing interval
Desloratadine products	Desloratadine	Prescription and premium positioning in some markets	Smaller commercial base

Loratadine’s main commercial advantage is the combination of once-daily dosing, broad consumer familiarity, and mature pediatric formulations. Its main weakness is limited ability to command a premium without a meaningful product improvement.

What Licensing Deals and Manufacturing Opportunities Exist?

There is limited value in licensing ordinary loratadine itself because the active ingredient is widely available. Licensing opportunities are more attractive in:

• Taste-masking technologies
• Pediatric flavor platforms
• Unit-dose liquid packaging
• Metered oral dispensers
• Low-sugar or sugar-free liquid systems
• Stability-enhancing excipient combinations
• Contract manufacturing capacity
• Regional brand rights
• Retailer-exclusive formulations

A technology owner could license a taste-masking platform to several manufacturers, subject to field-of-use restrictions. A finished-product company could license a recognized consumer-health brand into markets where pediatric antihistamine competition is less developed.

Manufacturing barriers are modest for standard tablets and liquids. More significant barriers arise in:

• Aseptic or low-bioburden liquid manufacturing
• High-throughput unit-dose filling
• Specialized orally disintegrating tablet equipment
• Flavor and taste-masking development
• Packaging-device assembly
• Stability testing across multiple container systems

What Revenue Exposure and Commercial Scenarios Apply?

Children's loratadine is generally a volume-driven, low-margin OTC opportunity. Revenue exposure is determined by channel and differentiation.

Scenario	Product profile	Revenue outlook
Commodity generic	Standard liquid or tablet	High volume, low margin
Retailer private label	Sugar-free or dye-free product	Predictable volume, limited pricing power
Premium branded liquid	Strong taste and dosing system	Higher gross margin, higher marketing cost
Unit-dose product	Preservative-free or travel format	Smaller volume, higher unit economics
International licensing	Region-specific pediatric product	Moderate investment, variable regulatory return
Combination platform	Loratadine with a differentiated device	Higher development cost and regulatory complexity

The most attractive near-term opportunity is a sugar-free, dye-free, alcohol-free liquid with a reliable oral syringe and a demonstrated taste advantage. The most defensible opportunity is a formulation-device combination supported by formulation patents, packaging rights, and retailer distribution.

Key Takeaways

• Children's loratadine is an established OTC product with no meaningful core-molecule exclusivity.
• Standard pediatric liquids are easy to replicate and face high generic and private-label pressure.
• Excipient strategy should focus on taste masking, sugar reduction, viscosity, preservative performance, and dose accuracy.
• Sugar-free, dye-free, alcohol-free, and unit-dose products provide the clearest commercial extensions.
• Stronger patents require demonstrated technical effects, not routine excipient substitution.
• The most defensible product combines a differentiated formulation, dispensing device, packaging, brand, and distribution agreement.
• Paragraph IV litigation and biosimilar risk are not central to conventional loratadine.
• The main regulatory risks involve pediatric labeling, inactive-ingredient qualification, stability, microbiological control, and dosing-device performance.
• Manufacturing barriers are low for standard products and higher for preservative-free, unit-dose, and advanced taste-masked formats.

FAQs About Children's Loratadine Excipient Strategy

Can Children's Loratadine be formulated without sugar?

Yes. Sugar-free products can use sorbitol, glycerin, sucralose, acesulfame potassium, or combinations of sweeteners. The formulation must maintain acceptable taste, viscosity, stability, and gastrointestinal tolerability.

Is propylene glycol appropriate in pediatric loratadine liquid?

Propylene glycol may be used as a co-solvent, but its concentration and cumulative pediatric exposure require product-specific evaluation. It should not be selected solely for manufacturing convenience.

What is the best preservative system for loratadine syrup?

An acidic benzoate-based system is common, but the optimal system depends on pH, packaging, microbial challenge performance, flavor, and in-use stability. Preservative selection must be validated in the final product.

Can a taste-masked loratadine product receive patent protection?

Yes, if the formulation produces a non-obvious technical result, such as materially reduced bitterness, improved stability, or superior dissolution. A simple change from sucrose to another sweetener is unlikely to support broad protection.

Is a biosimilar strategy relevant to Children's loratadine?

No. Loratadine is a small-molecule drug, not a biologic. Commercial competition comes from generics, OTC monograph products, private-label manufacturers, branded consumer-health companies, and differentiated formulations.

References

1. U.S. Food and Drug Administration. (2022). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use.
2. National Library of Medicine. (2024). DailyMed: Loratadine oral solution and tablet product labeling.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
5. U.S. Food and Drug Administration. (2023). Guidance for industry: Nonprescription drug product labeling.